Brief: Assembly Biosciences Announces Additional Promising Data From Phase 1A Clinical Trial Evaluating Highly Potent Next-Generation Core Inhibitor Candidate Abi-4334
18/04/2023 13:04
April 18 (Reuters) - Assembly Biosciences Inc ASMB.O :
* ASSEMBLY BIOSCIENCES ANNOUNCES ADDITIONAL PROMISING DATA
FROM
PHASE 1A CLINICAL TRIAL EVALUATING HIGHLY POTENT NEXT-GENERATION
CORE INHIBITOR CANDIDATE ABI-4334 AND PROVIDES PIPELINE UPDATE
* ASSEMBLY BIOSCIENCES-WILL EVALUATE PARTNERING OPTIONS FOR
ITS
CORE INHIBITOR PORTFOLIO PRIOR TO FURTHER CLINICAL DEVELOPMENT
OF MECHANISM FOR HBV CURE
* ASSEMBLY BIOSCIENCES-PHASE 1A CLINICAL DATA FOR REMAINING
200 MG
MULTIPLE DOSE COHORT FOR ABI-4334 CONTINUE TO DEMONSTRATE
ENCOURAGING CLINICAL PROFILE
* ASSEMBLY BIOSCIENCES INC - WITH REPRIORITIZATION OF
PROGRAMS,
CO'S ESTIMATED CASH RUNWAY EXTENDS INTO Q3 OF 2024
Source text for Eikon: ID:nGNX7v43d8
Further company coverage: ASMB.O